Loading...
BioVie Inc (BIVI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of trading signals, and no significant catalysts make it prudent to hold off on investing in this stock for now.
The MACD histogram is slightly positive (0.0148) but contracting, indicating weakening momentum. RSI is neutral at 57.196, suggesting no strong overbought or oversold conditions. Moving averages are converging, showing no clear trend. Support and resistance levels are close to the current price, with the pivot at 1.234.

No recent news, trading trends, or significant catalysts identified.
The stock price has been declining (-1.55% in regular market, -3.10% post-market). Financial performance is weak with declining net income (-15.19% YoY) and EPS (-83.08% YoY). No recent insider or hedge fund activity, and no congress trading data.
In Q2 2026, revenue remained at 0 with no growth. Net income dropped to -6,069,475 (-15.19% YoY), and EPS fell to -0.77 (-83.08% YoY). Gross margin remained at 0 with no improvement.
No data available for analyst ratings or price target changes.